Detalles de la búsqueda
1.
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Front Oncol
; 9: 1178, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31750258
Resultados
1 -
1
de 1
1
Próxima >
>>